Last updated: September 8, 2026
PREVNAR 13 generated peak annual sales of roughly $6 billion as Pfizer’s principal pneumococcal vaccine. Its U.S. adult franchise has been displaced by higher-valent products, including PREVNAR 20 and Merck’s CAPVAXIVE, while pediatric demand remains supported by routine immunization. The commercial outlook for PREVNAR 13 is therefore a managed decline in mature markets, partly offset by international sales and legacy pediatric use.
PREVNAR 13 Market Dynamics, Revenue Trajectory, Patents and Competitive Outlook
What is PREVNAR 13 and who markets it?
PREVNAR 13 is Pfizer’s 13-valent pneumococcal conjugate vaccine, also known as pneumococcal 13-valent conjugate vaccine or PCV13. It contains capsular polysaccharides from 13 Streptococcus pneumoniae serotypes conjugated to a carrier protein.
The product was developed through Wyeth, which Pfizer acquired in 2009. The FDA approved PREVNAR 13 for infants and young children in February 2010 and later expanded its label to adults and additional age groups.[1]
PREVNAR 13 is a biologic vaccine regulated under a biologics license application, or BLA. It is not an ordinary small-molecule drug marketed through an abbreviated new drug application, or ANDA.
| Attribute |
PREVNAR 13 |
| Active product |
13-valent pneumococcal conjugate vaccine |
| Sponsor |
Pfizer |
| U.S. regulatory pathway |
Biologics license application |
| Initial U.S. approval |
February 2010 |
| Primary uses |
Pediatric and adult pneumococcal disease prevention |
| Main successor product |
PREVNAR 20 |
| Main U.S. pediatric competitors |
VAXNEUVANCE and PREVNAR 20 |
| Main U.S. adult competitors |
PREVNAR 20 and CAPVAXIVE |
| Vaccine class |
Pneumococcal conjugate vaccine |
How has PREVNAR 13 revenue changed over time?
Pfizer reports revenue for the broader Prevnar family rather than consistently separating PREVNAR 13 from PREVNAR 20. The reported figures therefore represent franchise revenue, not pure PREVNAR 13 sales.
| Fiscal year |
Prevnar family revenue |
Market interpretation |
| 2018 |
Approximately $5.8 billion |
Mature global franchise |
| 2019 |
Approximately $5.8 billion |
Stable peak-period performance |
| 2020 |
Approximately $5.9 billion |
Pandemic-era supply and vaccination disruption were limited at the franchise level |
| 2021 |
Approximately $5.3 billion |
Transition pressure and market normalization |
| 2022 |
Approximately $6.3 billion |
PREVNAR 20 launch and broader franchise contribution |
| 2023 |
Approximately $6.4 billion |
Higher-valent product offset erosion of PREVNAR 13 |
Source: Pfizer annual reports and Form 10-K disclosures.[2-5]
The revenue profile has two distinct phases:
- PREVNAR 13 was the dominant product and generated multibillion-dollar annual sales.
- Pfizer shifted the franchise toward PREVNAR 20 after its 2021 approval, preserving pneumococcal vaccine revenue even as PREVNAR 13 lost adult share.
This distinction matters for valuation. Pfizer’s recent Prevnar revenue should not be treated as a direct proxy for PREVNAR 13 demand. A growing portion of reported franchise revenue comes from PREVNAR 20.
When did PREVNAR 13 lose exclusivity?
PREVNAR 13’s principal U.S. biologic exclusivity period has expired. The FDA approved the product in 2010, and the 12-year reference-product exclusivity period under the Public Health Service Act generally ran until 2022.[1,6]
That date did not create an automatic generic launch. Vaccines are complex biologics, and follow-on products generally require a separate BLA or a biosimilar application under Section 351(k) of the Public Health Service Act. A competitor must establish analytical similarity, manufacturing comparability, and clinical or immunogenicity support appropriate to the product.
The practical loss of exclusivity has been driven more by vaccine innovation and public-health recommendations than by a conventional generic launch. PREVNAR 20 and other higher-valent products offer broader serotype coverage and have been more important commercial threats than a direct copy of PREVNAR 13.
What patents protect PREVNAR 13?
PREVNAR 13 is protected by a layered intellectual-property estate covering:
- Pneumococcal polysaccharide-protein conjugates
- Serotype combinations
- Carrier-protein conjugation chemistry
- Vaccine formulations
- Manufacturing and purification processes
- Immunization methods and dosing schedules
There is no single public patent-expiration date that defines PREVNAR 13 market exclusivity. Patent protection varies by claim, jurisdiction, patent-family member, patent-term adjustment, and any applicable regulatory extension.
The product’s commercial position is also affected by know-how that is not fully captured by patent listings. Manufacturing a multivalent conjugate vaccine at scale requires validated processes, controlled polysaccharide quality, conjugation consistency, sterility assurance, and clinical comparability data.
Is PREVNAR 13 listed in the Orange Book?
PREVNAR 13 is not treated like a conventional small-molecule product with an Orange Book patent listing. The FDA Orange Book principally identifies approved drug products and patent information relevant to ANDA-based generic competition. PREVNAR 13 is licensed as a biologic under a BLA.
The relevant regulatory framework is the Purple Book and the Section 351(k) biosimilar pathway. The absence of a conventional Orange Book listing does not mean that the product lacks patent protection. It means that the patent-certification process differs from the Paragraph IV framework used for small-molecule generics.[7]
Are there Paragraph IV challenges to PREVNAR 13?
A conventional Paragraph IV challenge is not the expected route for PREVNAR 13 because Paragraph IV certifications apply to ANDA applicants challenging patents listed for small-molecule reference drugs.
A competing biologic would generally pursue one of two routes:
- A standalone 351(a) BLA for a new or competing vaccine
- A 351(k) biosimilar application, if the product qualifies under the statutory and scientific standards
For pneumococcal conjugate vaccines, a direct biosimilar strategy is difficult. The products contain multiple serotypes, complex conjugates, and product-specific manufacturing characteristics. A rival may obtain approval through an independent clinical and regulatory program rather than establish biosimilarity to PREVNAR 13.
Public competition has therefore emerged through differentiated higher-valent products rather than a known large-scale Paragraph IV campaign against PREVNAR 13.
What formulations and methods of use are protected?
The formulation estate is commercially important because pneumococcal vaccines combine multiple antigenic components in a single injectable product. Relevant protection can include:
- The 13-serotype antigen composition
- Aluminum-adjuvanted suspension formulations
- Conjugation ratios and carrier-protein relationships
- Stabilization and storage conditions
- Pediatric dosing schedules
- Adult revaccination and risk-based dosing
- Use in defined age or immunocompromised populations
Method-of-use protection is less commercially decisive than product-composition and manufacturing rights. Public-health recommendations, procurement contracts, and clinical guidelines determine which vaccine is used in practice.
How does PREVNAR 13 compare with PREVNAR 20, VAXNEUVANCE and CAPVAXIVE?
| Product |
Company |
Serotypes |
U.S. approval timing |
Commercial position |
| PREVNAR 13 |
Pfizer |
13 |
2010 |
Legacy pediatric and international product |
| VAXNEUVANCE |
Merck |
15 |
2021 |
Pediatric and adult competitor |
| PREVNAR 20 |
Pfizer |
20 |
2021 |
Pfizer’s principal adult successor |
| CAPVAXIVE |
Merck |
21 |
2024 |
Adult product designed to cover additional disease-causing serotypes |
PREVNAR 20 has the strongest direct effect on PREVNAR 13 because it is sold by the same company and allows Pfizer to migrate adult demand within its own franchise. The product was approved for adults and later received pediatric approval, strengthening Pfizer’s ability to maintain a unified higher-valent portfolio.[8]
VAXNEUVANCE gives Merck a competing conjugate-vaccine platform. CAPVAXIVE increases competitive pressure in adults, particularly where serotype coverage and residual invasive pneumococcal disease are central purchasing considerations.[9]
In the United States, CDC recommendations have progressively shifted away from routine standalone PCV13 use in adults. Current adult options include PCV15, PCV20 or PCV21 depending on age, prior vaccination history and medical risk factors.[10]
What is the FDA and CDC status of PREVNAR 13?
PREVNAR 13 remains an FDA-licensed product. Its market position has changed because of updated vaccine recommendations and the availability of higher-valent alternatives.
For children, U.S. recommendations have moved toward PCV15 or PCV20 for routine pneumococcal vaccination. PCV13 can remain relevant in certain product-completion or supply situations, but it is no longer the sole standard pediatric conjugate vaccine.
For adults, PCV20 and PCV21 offer broader serotype coverage and have reduced the role of PCV13 in primary vaccination. PREVNAR 13 may still matter where a patient has already received it or where a specific completion schedule applies.[10]
What generic, biosimilar and follow-on entry risks exist?
The risk of a direct generic-style launch is low because PREVNAR 13 is a complex multivalent vaccine rather than a simple chemical drug. The larger risks are:
- Product substitution by higher-valent conjugate vaccines.
- Loss of preferred status in government immunization schedules.
- Reduced adult demand after transition to PREVNAR 20 or PCV21.
- Pricing pressure from rival public-sector tenders.
- Manufacturing cost pressure if volume falls.
- International substitution by PCV15, PCV20 or other regional products.
A true follow-on vaccine could compete without being a biosimilar. An independently developed product with a different serotype composition may obtain its own BLA and compete on coverage, immunogenicity, price and supply reliability.
What patent litigation affects PREVNAR 13?
The main litigation risk is not a traditional ANDA Paragraph IV case. Any significant dispute would more likely involve:
- Patent infringement by a competing conjugate vaccine
- Licensing rights to pneumococcal conjugation technology
- Manufacturing-process patents
- Contract and procurement disputes
- Patent challenges in jurisdictions with active vaccine competition
No widely reported U.S. settlement involving a direct generic launch of PREVNAR 13 defines the current market. Pfizer’s commercial defense has relied primarily on next-generation product development, regulatory positioning and procurement relationships.
How strong is the PREVNAR 13 patent estate?
The estate is commercially meaningful but less decisive than it was before higher-valent vaccines entered the market.
| Factor |
Assessment |
| Composition patents |
Historically strong, but aging |
| Regulatory exclusivity |
Expired after the 12-year biologic period |
| Manufacturing know-how |
High barrier to replication |
| Formulation protection |
Relevant, but product-specific |
| Method-of-use protection |
Secondary to product and schedule recommendations |
| Biosimilar risk |
Moderate in theory, limited by product complexity |
| Direct generic risk |
Low under the ANDA model |
| Substitution risk |
High from higher-valent vaccines |
| Pfizer defensive position |
Strong through PREVNAR 20 and manufacturing scale |
Patent strength does not equal franchise strength. PREVNAR 13 can retain valuable patents while losing commercial share because physicians, payers and public-health agencies prefer broader serotype coverage.
What is the geographic outlook for PREVNAR 13?
The United States is the most advanced market in the shift toward higher-valent vaccines. International markets will transition at different speeds because national immunization programs vary in:
- Vaccine tender timing
- Budget constraints
- Serotype epidemiology
- Pediatric schedule design
- Local manufacturing policy
- Public reimbursement
PREVNAR 13 can retain international revenue where government contracts remain active or where higher-valent alternatives have not yet secured reimbursement. The product’s global decline is therefore likely to be gradual rather than uniform.
Manufacturing scale remains a competitive barrier. Pneumococcal conjugate vaccines require specialized production, quality-control systems and regulatory validation. A competitor needs more than antigen access to match Pfizer’s supply reliability.
What is the likely generic launch scenario for PREVNAR 13?
The most likely scenarios are:
| Scenario |
Probability assessment |
Commercial effect |
| Direct ANDA generic launch |
Low |
Minimal near-term impact |
| 351(k) biosimilar-style competitor |
Limited but possible |
Could pressure price if interchangeable |
| Independent higher-valent BLA |
Already occurring |
Main source of substitution |
| Continued pediatric legacy use |
Likely in selected markets |
Supports residual demand |
| Rapid U.S. adult erosion |
High |
Accelerates migration to PCV20 and PCV21 |
| International gradual decline |
Likely |
Extends tail revenue |
The economic value of PREVNAR 13 is now concentrated in residual pediatric demand, international programs and patients whose vaccination histories require product-specific completion. Pfizer’s larger strategic asset is the Prevnar franchise, not PREVNAR 13 as a standalone product.
Key Takeaways
- PREVNAR 13 was one of Pfizer’s largest vaccine products, with peak franchise revenue near $6 billion annually.
- Pfizer does not consistently report PREVNAR 13 separately from the broader Prevnar family.
- The product’s 12-year U.S. biologic exclusivity period has expired.
- PREVNAR 13 is not subject to the standard Orange Book and Paragraph IV framework used for small-molecule drugs.
- Higher-valent vaccines, particularly PREVNAR 20, are the principal commercial threat.
- U.S. adult demand has shifted sharply toward PCV20 and PCV21.
- Pediatric and international sales provide the remaining commercial base.
- Manufacturing know-how and supply scale remain meaningful barriers to direct replication.
- The leading risk is therapeutic and policy substitution, not a conventional generic launch.
- Pfizer has protected franchise economics by migrating customers from PREVNAR 13 to PREVNAR 20.
FAQs About PREVNAR 13 Exclusivity, Patents and Market Share
Does PREVNAR 13 still have market exclusivity?
Its 12-year U.S. reference-product biologic exclusivity period has ended. Commercial protection now depends on patents, manufacturing barriers, regulatory approvals, contracts and residual clinical use.
Can a generic company make PREVNAR 13?
A conventional ANDA generic is not the expected pathway. A competitor would generally need an independent BLA or potentially a 351(k) biosimilar application.
Is PREVNAR 13 still recommended for adults?
Adult recommendations have shifted toward PCV20 or PCV21, although PREVNAR 13 can remain relevant for certain patients based on prior vaccination and completion schedules.
Is PREVNAR 20 replacing PREVNAR 13?
Yes, PREVNAR 20 is Pfizer’s principal successor product, especially in adults. It provides broader serotype coverage and allows Pfizer to retain customers within the Prevnar franchise.
What is the main investment risk for PREVNAR 13?
The main risk is declining standalone demand as public-health recommendations and clinical practice shift to higher-valent pneumococcal vaccines.
References
- U.S. Food and Drug Administration. (2010). Prevnar 13 prescribing information.
- Pfizer Inc. (2020). 2020 annual report.
- Pfizer Inc. (2021). 2021 annual report.
- Pfizer Inc. (2022). 2022 annual report.
- Pfizer Inc. (2023). 2023 annual report.
- U.S. Congress. (2010). Patient Protection and Affordable Care Act, Section 7002: User fees for biological products.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2021). Prevnar 20 prescribing information.
- U.S. Food and Drug Administration. (2024). Capvaxive prescribing information.
- Centers for Disease Control and Prevention. (2024). Pneumococcal vaccine recommendations.
